Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of C4 Therapeutics Inc (NASDAQ: CCCC) was $2.58 for the day, down -0.39% from the previous closing price of $2.59. In other words, the price has decreased by -$0.39 from its previous closing price. On the day, 1.01 million shares were traded. CCCC stock price reached its highest trading level at $2.61 during the session, while it also had its lowest trading level at $2.5.
Ratios:
Our analysis of CCCC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.76 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.36.
On September 17, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $8.
Stephens Upgraded its Equal-Weight to Overweight on September 15, 2025, while the target price for the stock was maintained at $6.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 18 ’25 when Boyle Scott N sold 669 shares for $3.15 per share. The transaction valued at 2,107 led to the insider holds 107,805 shares of the business.
Boyle Scott N sold 490 shares of CCCC for $1,544 on Feb 14 ’25. The Chief Business Officer now owns 110,842 shares after completing the transaction at $3.15 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 250039184 and an Enterprise Value of 119618200. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.30 while its Price-to-Book (P/B) ratio in mrq is 1.24. Its current Enterprise Value per Revenue stands at 3.973 whereas that against EBITDA is -1.022.
Stock Price History:
The Beta on a monthly basis for CCCC is 2.91, which has changed by -0.40046299 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, CCCC has reached a high of $4.89, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is 6.08%, while the 200-Day Moving Average is calculated to be 23.50%.
Shares Statistics:
CCCC traded an average of 2.08M shares per day over the past three months and 1727040 shares per day over the past ten days. A total of 96.91M shares are outstanding, with a floating share count of 77.61M. Insiders hold about 19.92% of the company’s shares, while institutions hold 57.44% stake in the company. Shares short for CCCC as of 1764288000 were 5588028 with a Short Ratio of 2.69, compared to 1761868800 on 4811669. Therefore, it implies a Short% of Shares Outstanding of 5588028 and a Short% of Float of 6.1.
Earnings Estimates
Its stock is currently analyzed by 3.0 different market analysts. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.33 and -$1.71 for the fiscal current year, implying an average EPS of -$1.52. EPS for the following year is -$1.29, with 3.0 analysts recommending between -$1.15 and -$1.55.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $8M to a low estimate of $100k. As of. The current estimate, C4 Therapeutics Inc’s year-ago sales were $5.18M
A total of 6 analysts have provided revenue estimates for CCCC’s current fiscal year. The highest revenue estimate was $35M, while the lowest revenue estimate was $25M, resulting in an average revenue estimate of $30.39M. In the same quarter a year ago, actual revenue was $35.58M
